医药新股闹涨“A+H市场”

Group 1 - The core viewpoint of the article highlights the successful debut of two pharmaceutical stocks, Baiaosaitu and Baoji Pharmaceutical, on December 10, with significant price increases of 146.6% and 138.8% respectively [1][3][4] - Baiaosaitu achieved a dual listing on both the STAR Market and the Hong Kong Stock Exchange, with 75.21% of its shares circulating in A-shares and 24.79% in H-shares [4] - The overall performance of newly listed pharmaceutical stocks in 2023 has been strong, with 8 A-share and 24 Hong Kong stocks debuting, many of which saw first-day gains exceeding 100% [1][8] Group 2 - Baiaosaitu reported a revenue of approximately 6.21 billion yuan in the first half of the year, marking a year-on-year growth of 51.27%, and achieved a net profit of about 479.99 million yuan, indicating a turnaround from previous losses [6] - In contrast, Baoji Pharmaceutical has not yet turned a profit, with revenues of 6.93 million yuan in 2023 and a net loss of approximately 1.6 billion yuan [7] - The market's optimistic outlook on the high growth potential of the biopharmaceutical industry and the scarcity of new stocks has driven investor sentiment, despite potential valuation bubble risks [5]